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ABSTRACT
Introduction Acute respiratory distress syndrome 
(ARDS) is the major cause of mortality in patients with 
SARS- CoV-2 pneumonia. It appears that development of 
‘cytokine storm’ in patients with SARS- CoV-2 pneumonia 
precipitates progression to ARDS. However, severity 
scores on admission do not predict severity or mortality 
in patients with SARS- CoV-2 pneumonia. Our objective 
was to determine whether patients with SARS- CoV-2 
ARDS are clinically distinct, therefore requiring alternative 
management strategies, compared with other patients 
with ARDS. We report a single- centre retrospective study 
comparing the characteristics and outcomes of patients 
with ARDS with and without SARS- CoV-2.
Methods Two intensive care unit (ICU) cohorts of patients 
at the Queen Elizabeth Hospital Birmingham were 
analysed: SARS- CoV-2 patients admitted between 11 
March and 21 April 2020 and all patients with community- 
acquired pneumonia (CAP) from bacterial or viral infection 
who developed ARDS between 1 January 2017 and 1 
November 2019. All data were routinely collected on the 
hospital’s electronic patient records.
Results A greater proportion of SARS- CoV-2 patients 
were from an Asian ethnic group (p=0.002). SARS- CoV-2 
patients had lower circulating leucocytes, neutrophils 
and monocytes (p<0.0001), but higher CRP (p=0.016) on 
ICU admission. SARS- CoV-2 patients required a longer 
duration of mechanical ventilation (p=0.01), but had lower 
vasopressor requirements (p=0.016).
Discussion The clinical syndromes and respiratory 
mechanics of SARS- CoV-2 and CAP- ARDS are broadly 
similar. However, SARS- CoV-2 patients initially have 
a lower requirement for vasopressor support, fewer 
circulating leukocytes and require prolonged ventilation 
support. Further studies are required to determine whether 
the dysregulated inflammation observed in SARS- CoV-2 
ARDS may contribute to the increased duration of 
respiratory failure.
INTRODUCTION
SARS- CoV-2 pneumonia can progress to 
hypoxaemic respiratory failure requiring 
mechanical ventilation, with patients 
fulfilling the Berlin criteria for acute respira-
tory distress syndrome (ARDS).1–3 Inten-
sive care unit (ICU) mortality rates of up 
to 68% from SARS- CoV-2 ARDS have been 
reported.3 4 A multinational study undertaken 
prior to the SARS- CoV-2 pandemic found that 
pneumonia was the underlying risk factor in 
59% of ARDS cases.5 Recently, a retrospec-
tive cohort study undertaken in Wuhan, 
China found that 41.8% of adult patients 
admitted with SARS- CoV-2 pneumonia devel-
oped ARDS.6 Risk factors for mortality from 
SARS- CoV-2 pneumonia include increasing 
age, coronary heart disease, diabetes mellitus 
and chronic kidney disease.7 8 Admission 
CURB-65 scores do not predict severity or 
mortality in patients with SARS- CoV-2 pneu-
monia, due to a rapidly progressing clinical 
course.7 However, lymphopenia, eosinopenia 
and elevated acute phase proteins are predic-
tors of increased disease severity.7 9 10
It appears that development of ‘cyto-
kine storm’ in patients with SARS- CoV-2 
pneumonia is associated with progression 
to ARDS, however, the cytopathic effects 
of the viral pneumonia may be just as 
Key messages
 ► This is the first UK study comparing the clinical 
characteristics and outcomes of acute respiratory 
distress syndrome (ARDS) secondary to pneumonia 
in patients with and without SARS- CoV-2.
 ► Are patients with SARS- CoV-2 ARDS clinically dis-
tinct to other patients with ARDS, therefore, requiring 
alternative management strategies?
 ► While the clinical syndromes of ARDS secondary to 
SARS- CoV-2 and community- acquired pneumonia 
are similar, SARS- CoV-2 patients initially have a low-
er requirement for vasopressor support and require 
prolonged ventilation support.
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important.9 11 12 Histological analysis of postmortem lung 
tissue from SARS- CoV-2 pneumonia patients has shown 
diffuse alveolar damage (DAD).13 14 The presence of 
DAD has previously been used to identify a subphenotype 
of ARDS with higher mortality.15 16 These findings suggest 
that a similar pathological process occurs in patients with 
ARDS with and without SARS- CoV-2.
Our objective was to determine whether patients with 
SARS- CoV-2 ARDS are clinically distinct, therefore, 
requiring alternative management strategies, compared 
with other patients with ARDS.17 This retrospective study 
provides clinical characterisation of ARDS patients with 
and without SARS- CoV-2 admitted to a single- centre ICU.
METHODS
This is a single- centre, observational, retrospective 
study from the ICU of the Queen Elizabeth Hospital 
Birmingham, UK. All data were routinely collected on the 
hospital’s electronic patient records. Only data that were 
obtained as part of routine clinical care were collected 
for this study. All data were anonymised and entered by 
the Local Clinical Care Team, without linkage to any 
patient identifiers, in accordance with national and local 
guidance.
Two ICU cohorts of patients were analysed: SARS- CoV-2 
pneumonia patients admitted between 11 March and 
21 April 2020 (online supplemental figure 1) and all 
patients with community- acquired pneumonia (CAP) 
from bacterial or viral infection who developed ARDS 
between 1 January 2017 and 1 November 2019 (online 
supplemental figure 2). Patients who developed hospital- 
acquired pneumonia (HAP: defined as onset >48 hours 
after hospital admission) were excluded. This was to iden-
tify a more relevant, directly comparable control group, 
in which infection was acquired in the community, and 
pneumonia was present at hospital admission. The caus-
ative organisms and clinical course of CAP and HAP 
also differ significantly. Patients with ARDS secondary to 
others causes were also excluded. The sample sizes were 
determined pragmatically, to include all SARS- CoV-2 
pneumonia patients admitted to the ICU within the first 
6 weeks of the pandemic. The sample size of the CAP- 
ARDS control group included all such patients within the 
3 years preceding the pandemic, since all these patients 
would have their hospital records within a rapidly acces-
sible electronic system, and would have received proto-
colised management similar to that received by the 
SARS- CoV-2 ARDS patients.
As patients were from the same institution, their 
management prior to ICU admission and on ICU were 
broadly similar following local evidence- based protocols 
and national guidelines5 with respect to interventions 
that affect outcome including low tidal volume ventila-
tion and prone positioning (online supplemental table 
1). High frequency oscillatory ventilation was only used as 
a rescue therapy in patients with refractory severe respira-
tory failure who were not accepted by an extracorporeal 
membrane oxygenation centre, and were managed as 
per previously published algorithms.18 All patients were 
intubated, sedated and mechanically ventilated with 
positive pressure ventilation. Baseline demographic, 
comorbidities, laboratory investigations, physiological 
parameters and severity scores (Acute Physiology And 
Chronic Health Evaluation II [APACHE II], Sequential 
Organ Failure Assessment [SOFA] and Murray Lung 
Injury) were collected at ICU admission. Sequential phys-
iological and laboratory parameters were collected for 7 
days whist on ICU. Sequential data are not available for 
all patients due to deaths of 15 SARS- CoV-2 and 5 CAP- 
ARDS patients within 1 week.
Statistical analysis was performed using GraphPad 
Prism version 8.0. Data distributions were non- parametric 
and are presented as median with IQR for continuous 
variables and number (percentage) for categorical vari-
ables. Differences between patient groups were analysed 
using Mann- Whitney- U test for continuous data and Fish-
er’s exact test for categorical data. Two- sided tests were 
used for all comparisons with p<0.05 considered statisti-
cally significant.
RESULTS
A total of 111 patients with SARS- CoV-2 ARDS and 
29 patients with CAP- ARDS met the inclusion criteria 
(table 1). Many patients (n=33) screened for CAP- ARDS 
were excluded, as pneumonia had developed >48 hours 
after hospital admission. Patient demographic details 
are shown in table 1, with both groups being broadly 
similar except for ethnic background. A greater propor-
tion of SARS- CoV-2 patients were of Asian/Asian British 
ethnicity (p=0.002), and a lower proportion were of 
White ethnicity (p=0.012), compared with CAP- ARDS 
patients
On ICU admission, SARS- CoV-2 patients had signifi-
cantly lower APACHE- II and SOFA scores than CAP- ARDS 
patients (see table 1: p<0.0001). SOFA scores remained 
lower in SARS- CoV-2 patients for 7 days following ICU 
admission (figure 1A).
SARS- CoV-2 patients had lower circulating leukocytes, 
neutrophils and monocytes (p<0.0001 for all) than CAP- 
ARDS patients on ICU admission. Leucocytes and neutro-
phil counts remained lower in SARS- CoV-2 patients for 3 
days following ICU admission, whereas monocyte counts 
remained lower for 6 days (figure 1B–D). Albumin was 
lower (p=0.003) while CRP (p=0.016) and platelet count 
(p=0.029) were higher at ICU admission in SARS- CoV-2 
patients. Differences in CRP and albumin between patient 
groups increased with duration of ICU stay (figure 1E,F). 
There was no difference in lymphocytes, eosinophils, bili-
rubin or creatinine between groups on ICU admission.
Positive end- expiratory pressure (PEEP) was higher 
(p=0.003) and tidal volumes were lower (p=0.006) 
in SARS- CoV-2 patients on ICU admission. However, 
there was no difference in other ventilator parameters 
between groups on ICU admission, including driving 
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Table 1 Demographics, laboratory and physiological characteristics of SARS- CoV-2 ARDS and CAP- ARDS patients on 
admission to ICU
SARS- CoV-2 ARDS (n=111) CAP- ARDS (n=29) P value
Demographics
Age at admission (years) 56 (47–63) 55 (41–59) 0.315*
Gender, male (n, %) 84 (75.7%) 19 (65.5%) 0.358†
Body mass index 29 (27–34) 29 (26–33) 0.403*
Ethnicity
White 54 (48.6%) 22 (75.8%) 0.012†
Asian/Asian British 34 (30.6%) 1 (3.4%) 0.002†
Black/African/Caribbean 9 (8.1%) 0 (0%) 0.204†
Mixed/multiple 3 (2.7%) 1 (3.4%) 0.999†
Other 10 (9.0%) 5 (17.2%) 0.308†
Comorbidities
None 30 (27.0%) 10 (34.5%) 0.490†
Hypertension 44 (39.6%) 9 (31.0%) 0.520†
Obesity 55 (49.5%) 12 (41.4%) 0.532†
Ischaemic heart disease 6 (5.4%) 1 (3.4%) >0.999†
Diabetes 33 (29.7%) 4 (13.8%) 0.100†
Asthma/COPD 12 (10.8%) 4 (13.8%) 0.743†
Stroke/TIA 3 (2.7%) 1 (3.4%) 0.999†
Chronic kidney disease 9 (8.1%) 1 (3.4%) 0.688†
Cancer 7 (6.3%) 3 (10.3%) 0.432†
Severity scoring
APACHE II 14 (12–18) 18 (16–24) 0.0002*
SOFA Score 8 (7–10) 12 (9–14) <0.0001*
Murray Lung Injury Score 2.75 (2.5–3.0) 2.75 (2.33–3.00) 0.645*
Laboratory parameters on ICU admission
White cell count (x109/L) 9.0 (5.9–12.6) 14.6 (10.6–22.9) <0.0001*
Neutrophils (x109/L) 6.9 (4.5–10.2) 12.7 (9.0–21.0) <0.0001*
Lymphocyte (x109/L) 0.88 (0.57–1.20) 0.7 (0.5–1.2) 0.327*
Monocytes (x109/L) 0.43 (0.29–0.65) 0.9 (0.6–1.3) <0.0001*
Eosinophils (x109/L) 0 (0–0.03) 0 (0–0.1) 0.277*
CRP (mg/L) 172 (113–241) 91 (40–235) 0.016*
Platelets (109/L) 224 (174–305) 191 (111–294) 0.029*
Creatinine (µmol/L) 77 (64–111) 87 (67–178) 0.260*
Bilirubin (µmol/L) 12 (9–20) 18 (8–45) 0.141*
Albumin (g/L) 27 (24–32) 31 (27–35) 0.003*
Ventilator parameters on ICU admission
Ppeak (cmH2O) 27 (24–30) 28 (24–30) 0.578*
PEEP (cmH2O) 10 (8–12) 8 (6–10) 0.003*
Driving pressure (cmH2O) 16 (14–19) 19 (14–22) 0.178*
Tidal volume (mL/ kg) 5.11 (4.60–5.89) 5.98 (4.87–6.96) 0.013*
Pulmonary compliance (mL/cmH2O) 28 (24–34) 25 (22–34) 0.471*
FiO2 (%) 70 (60–86) 80 (60–100) 0.149*
ICU outcomes
Hospital mortality 40 (36.0%) 12 (41.4%) 0.668†
Time to death from ICU admission (days) 11 (8–18) 11 (7–17) 0.874*
ICU LoS (days) 17 (10–24) 13 (9–24) 0.344*
Continued
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pressure, peak inspiratory pressure, pulmonary compli-
ance, fraction of inspired oxygen and PaO2 / FiO2 ratio. 
SARS- CoV-2 patients required a lower dose of vasopres-
sors on ICU admission (p=0.016).
SARS- CoV-2 patients required a longer duration 
of mechanical ventilation compared with CAP- ARDS 
patients (p=0.010). However, there was no significant 
difference in other major ICU outcomes between groups, 
including hospital mortality, ICU length of stay, time to 
death from ICU admission, development of moderate/
severe ARDS, need for renal replacement therapy or 
need for tracheostomy.
DISCUSSION
The stark difference between patient numbers indicates 
that before the emergence of SARS- CoV-2, development 
of CAP- ARDS was comparatively rare. In keeping with 
previous findings, our study confirms that SARS- CoV-2 
pneumonia seems to disproportionately affect patients 
from some ethnic minority backgrounds compared with 
CAP- ARDS.19
Patients with SARS- CoV-2 ARDS develop rapid respi-
ratory failure, however other organ functions seem to 
be initially preserved, with reduced requirement for 
vasopressors on ICU admission. Severity scores (SOFA, 
APACHE- II) were higher in the CAP- ARDS group on 
ICU admission. Similar observations were made in a 
study comparing patients with SARS- CoV-2 versus H1N1 
Influenza,20 suggesting that SARS- CoV-2 pneumonia 
initially causes less severe ARDS compared with CAP- 
ARDS patients who present with mainly bacterial infec-
tions or Influenza. However, the increased duration of 
respiratory failure in SARS- CoV-2 ARDS patients indi-
cates that existing severity scores may not be predictive 
in this population.
The lower circulating leucocyte and neutrophil count 
in SARS- CoV-2 ARDS is similar to that observed in a 
previous paediatric study comparing pneumonia patients 
with SARS- CoV-2 vs Influenza A.21 However, in contrast to 
this study, we found that CRP was significantly elevated 
in SARS- CoV-2 patients. Reduced circulating leukocytes 
in SARS- CoV-2 ARDS patients may indicate a greater 
migration of neutrophils and monocytes into the alve-
olar space, impaired leukopoiesis or increased leucocyte 
clearance. Further studies are required to elucidate the 
relationship between the observed elevated acute phase 
proteins and lower circulating leucocytes, which may lead 
to a greater understanding of SARS- CoV-2 pathogenesis.
While the duration of mechanical ventilation in CAP- 
ARDS patients was similar to previous ARDS cohorts,5 
the SARS- CoV-2 patients required an increased duration 
of mechanical ventilation. However, there was no signif-
icant difference in most ventilator parameters or other 
major ICU outcomes (eg, mortality and ICU length of 
stay) between patient groups. Absolute differences in 
PEEP and tidal volume between patient groups on ICU 
admission were small. The requirement for prolonged 
ventilation support is a key feature of SARS- CoV-2 ARDS, 
which otherwise causes a clinical syndrome similar to that 
observed in CAP- ARDS.
Although our CAP- ARDS tracheostomy rates may be 
considered high by some standards,5 they are similar to 
those in other primary ARDS cohorts from European 
nations,22 and thus they do not reflect outlying clinical 
behaviour. Our recent article currently in press (https:// 
bjanaesthesia. org/ article/ S0007- 0912( 20) 30678- 4/ full-
text) shows that we did not treat our SARS- CoV-2 patients 
any differently to our CAP- ARDS patients with regards to 
tracheostomy decisions, hence there being no significant 
difference between the groups.
A recent multicentre study by Grasselli et al has also 
compared SARS- CoV-2 ARDS patients with an earlier 
ARDS patient cohort unrelated to SARS- CoV-2.23 In 
contrast to our results, lung compliance was found to 
SARS- CoV-2 ARDS (n=111) CAP- ARDS (n=29) P value
ARDS (PaO2 / FiO2 ratio kPa)
  Mild (>26.6–40) 6 (5.4%) 2 (6.9%) 0.670†
  Moderate (>13.3 ≤26.6) 58 (52.3%) 15 (51.7%) 0.999†
  Severe (≤13.3) 47 (42.3%) 12 (41.4%) 0.999†
Day 1 PaO2 / FiO2 ratio (kPa) 15 (12–17) 15 (11–17) 0.895*
Duration of mechanical ventilation (days) 15 (9–20) 9 (3–17) 0.012*
Maximum norepinephrine dose on day 1 of ICU 
admission (µg/kg/min)
0.067 (0.015–0.120) 0.490 (0–0.623) 0.016*
Need for RRT 46 (41.4%) 11 (37.9%) 0.833†
Need for tracheostomy 55 (49.5%) 16 (55.2%) 0.678†
Data are n (%) or median (IQR). Tidal volume calculated using predicted body weight.
*Represents p- values from a Mann- Whitney U test.
†Represents p- values from a Fisher’s exact test.
APACHE II, Acute Physiology And Chronic Health Evaluation II; ARDS, acute respiratory distress syndrome; CAP, community- acquired pneumonia; 
COPD, chronic obstructive pulmonary disease; FiO2, fraction of inspired oxygen; ICU, intensive care unit; LoS, length of stay; PaO2, partial pressure 
of oxygen; PEEP, positive end- expiratory pressure; RRT, renal replacement therapy; SOFA, Sequential Organ Failure Assessment.
Table 1 Continued
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be reduced in SARS- CoV-2 ARDS patients. A subset of 
patients with SARS- CoV-2 ARDS with low compliance and 
elevated D- dimers were found to have an increased risk 
of mortality. Our study may have been underpowered 
to detect a difference in compliance, as the number of 
patients included within our study was lower. However, 
the control group used by Grasselli et al was significantly 
different to ours, with pneumonia being the underlying 
aetiology in only 57.6% of these patients, compared with 
100% in our study.23
Several laboratory parameters relevant to SARS- CoV-2 
patients including ferritin, lactate dehydrogenase 
and d- dimer6 23 were not included in our comparison, 
because only a small minority of patients in the CAP- 
ARDS control group had received these investigations. 
Data regarding the incidence of ARDS in CAP patients 
were also not available. Despite inclusion of all patients 
meeting the eligibility criteria at our centre, one of 
the largest ICU facilities in Europe, the power of our 
study was low due to the small size of the CAP- ARDS 
Figure 1 SOFA score and haematological parameters for SARS- CoV-2 and CAP- ARDS patients over the first 7 days in the 
ICU. (A) SOFA score. B: leucocyte count. (C): neutrophil count. (D) monocyte count. (E): CRP. (F): albumin. Data presented 
as daily median values and IQRs for SARS- CoV-2 ARDS and CAP- ARDS patients. A Mann- Whitney U test was performed 
at each time point to compare both patient groups: *P<0.05, **p<0.01, ***p<0.001, ****p<0.0001. ARDS, acute respiratory 
distress syndrome; CAP, community- acquired pneumonia; ICU, intensive care unit; SOFA, Sequential Organ Failure 
Assessment Score.
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cohort. There is also a temporal bias in our data, with 
the SARS- CoV-2 cases being newer. These are significant 
limitations of our study. Another important limitation 
of our study is its single- centre observational nature, 
thus its applicability to a broader range of patients is 
difficult.
In summary, we show that while the respiratory 
mechanics of SARS- CoV-2 and CAP- ARDS patients 
are similar, SARS- CoV-2 patients initially have a lower 
requirement for vasopressor support, fewer circulating 
leucocytes and require prolonged ventilation support. 
We do not recommend changes to the current manage-
ment of SARS- CoV-2 ARDS based on this study. However, 
further studies are required to determine whether the 
dysregulated inflammation observed in SARS- CoV-2 
patients contributes to the increased duration of respi-
ratory failure.
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